Granted Patent
B2
US 12,428,493 · App. 18/656,081 · Granted Sep 30, 2025
Antibodies that bind PSMA and gamma-delta T cell receptors
Inventors:
Robertus Cornelis Roovers (Utrecht, NL); Johannes Jelle Van Der Vliet (Amsterdam, NL); Lisa Anna King (Amsterdam, NL); Paul Willem Henri Ida Parren (Utrecht, NL); Victoria Iglesias Guimarais (Utrecht, NL); David Lutje Hulsik (Utrecht, NL); Peter Alexander Gerardus Maria Machielsen (Utrecht, NL)
Assignee:
LAVA THERAPEUTICS N.V.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to antibodies capable of binding human PSMA and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
Claims (9)
1. A bispecific antibody, comprising (a) a first polypeptide comprising SEQ ID NO: 26; and
(b) a second polypeptide comprising SEQ ID NO: 25.
2. A nucleic acid construct encoding the bispecific antibody of claim 1 .
3. An expression vector comprising the polynucleotide nucleic acid construct of claim 2 .
4. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable excipient.
5. A method of treating a cancer in a subject in need thereof comprising administering the bispecific antibody of claim 1 .
6. The method according to claim 5 , wherein the cancer is a prostate cancer, a colorectal cancer, a lung cancer, a breast cancer, an endometrial and ovarian cancer, a gastric cancer, a renal cell cancer, an urothelial cancer, a hepatocellular cancer, an oral squamous cancer, a thyroid tumor, an adenoid cystic carcinoma, or a glioblastoma.
7. The method according to claim 6 , wherein the prostate cancer is metastatic or non-metastatic prostate cancer.
8. The method according to claim 5 , further comprising administering an additional therapeutic agent.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 5, 2024
From: ROOVERS, ROBERTUS CORNELIS; VAN DER VLIET, JOHANNES JELLE; KING, LISA ANNA; PARREN, PAUL WILLEM HENRI IDA; IGLESIAS GUIMARAIS, VICTORIA; LUTJE HULSIK, DAVID; MACHIELSEN, PETER ALEXANDER GERARDUS MARIA
To: LAVA THERAPEUTICS N.V.
Reel/Frame 068146/0180 →
Priority Claims (1)
EP 20184800
· Jul 8, 2020
· regional
Continuity (2)
Continuation
18014457
References Cited (160)
US 5723309A
· Bonneville
· 1998
[cited by applicant]
US 6737398B1
· Gelfand et al.
· 2004
[cited by applicant]
US 7582300B2
· Gelfand et al.
· 2009
[cited by applicant]
US 7728114B2
· Mach et al.
· 2010
[cited by applicant]
US 7811564B2
· Cuello et al.
· 2010
[cited by applicant]
US 7875278B2
· Cardarelli et al.
· 2011
[cited by applicant]
US 8114965B2
· Maddon et al.
· 2012
[cited by applicant]
US 8153426B2
· Moser et al.
· 2012
[cited by applicant]
US 8178098B2
· Lahn et al.
· 2012
[cited by applicant]
US 8338173B2
· Moser et al.
· 2012
[cited by applicant]
US 8461308B2
· Cardarelli et al.
· 2013
[cited by applicant]
US 8470330B2
· Maddon et al.
· 2013
[cited by applicant]
US 9695248B2
· Maddon et al.
· 2017
[cited by applicant]
US 9708412B2
· Baeuerle et al.
· 2017
[cited by applicant]
US 20190263908A1
· Van Der Vliet et al.
· 2019
[cited by applicant]
US 20210095047A1
· Baeuerle et al.
· 2021
[cited by applicant]
US 20210100902A1
· DuBridge et al.
· 2021
[cited by applicant]
US 20210284730A1
· Ganesan et al.
· 2021
[cited by applicant]
US 20230272110A1
· Roovers et al.
· 2023
[cited by applicant]
EP 1229790A1
· 2002
[cited by applicant]
EP 1778836B1
· 2010
[cited by applicant]
EP 2360169A2
· 2011
[cited by applicant]
EP 1587837B1
· 2012
[cited by applicant]
EP 3297672A1
· 2018
[cited by applicant]
EP 3105252B1
· 2019
[cited by applicant]
EP 3544629A1
· 2019
[cited by applicant]
EP 3544997A1
· 2019
[cited by applicant]
EP 4118121A1
· 2023
[cited by applicant]
WO WO0122816A1
· 2001
[cited by applicant]
WO WO02080967A1
· 2002
[cited by applicant]
WO WO03034903A2
· 2003
[cited by applicant]
WO WO03068821A2
· 2003
[cited by applicant]
WO WO03080672A1
· 2003
[cited by applicant]
WO WO2004062551A2
· 2004
[cited by applicant]
WO WO2004067570A2
· 2004
[cited by applicant]
WO WO2005042029A2
· 2005
[cited by applicant]
WO WO2005046711A2
· 2005
[cited by applicant]
WO WO2006017954A1
· 2006
[cited by applicant]
WO WO2006089230A2
· 2006
[cited by applicant]
WO WO2006089231A2
· 2006
[cited by applicant]
WO WO2006125481A1
· 2006
[cited by applicant]
WO WO2007038658A2
· 2007
[cited by applicant]
WO WO2008006895A2
· 2008
[cited by applicant]
WO WO2009046294A2
· 2009
[cited by applicant]
WO WO2009130575A2
· 2009
[cited by applicant]
WO WO2010118522A1
· 2010
[cited by applicant]
WO WO2012145714A2
· 2012
[cited by applicant]
WO WO2013110531A1
· 2013
[cited by applicant]
WO WO2013138400A1
· 2013
[cited by applicant]
WO WO2013147606A1
· 2013
[cited by applicant]
WO WO2013173820A2
· 2013
[cited by applicant]
WO WO2013174403A1
· 2013
[cited by applicant]
WO WO2013174404A1
· 2013
[cited by applicant]
WO WO2013174509A1
· 2013
[cited by applicant]
WO WO2013174510A1
· 2013
[cited by applicant]
WO WO2014012479A1
· 2014
[cited by applicant]
WO WO2014055097A1
· 2014
[cited by applicant]
WO WO2014127785A1
· 2014
[cited by applicant]
WO WO2014127906A1
· 2014
[cited by applicant]
WO WO2015044386A1
· 2015
[cited by applicant]
WO WO2015121383A1
· 2015
[cited by applicant]
WO WO2015156673A1
· 2015
[cited by applicant]
WO WO2016081518A2
· 2016
[cited by applicant]
WO WO2016145139A1
· 2016
[cited by applicant]
WO WO2016165302A1
· 2016
[cited by applicant]
WO WO2016179518A2
· 2016
[cited by applicant]
WO WO2016180969A1
· 2016
[cited by applicant]
WO WO2016187594A1
· 2016
[cited by applicant]
WO WO2017023761A1
· 2017
[cited by applicant]
WO WO2017053856A1
· 2017
[cited by applicant]
WO WO2017121905A1
· 2017
[cited by applicant]
WO WO2017122017A1
· 2017
[cited by applicant]
WO WO2017122018A1
· 2017
[cited by applicant]
WO WO2017122019A1
· 2017
[cited by applicant]
WO WO2017180713A1
· 2017
[cited by applicant]
WO WO2017185662A1
· 2017
[cited by applicant]
WO WO2018023111A1
· 2018
[cited by applicant]
WO WO2018071777A1
· 2018
[cited by applicant]
WO WO2018098354A1
· 2018
[cited by examiner]
WO WO2018098356A1
· 2018
[cited by applicant]
WO WO2018140831A2
· 2018
[cited by applicant]
WO WO2018229163A1
· 2018
[cited by applicant]
WO WO2019055841A1
· 2019
[cited by applicant]
WO WO2019070424A1
· 2019
[cited by applicant]
WO WO2019195535A1
· 2019
[cited by applicant]
WO WO2019224718A2
· 2019
[cited by applicant]
WO WO2019245991A1
· 2019
[cited by applicant]
WO WO2019246514A
· 2019
[cited by examiner]
WO WO2020010250A2
· 2020
[cited by applicant]
WO WO2020060406A1
· 2020
[cited by examiner]
WO WO2020060405A1
· 2020
[cited by applicant]
WO WO2020159368A1
· 2020
[cited by applicant]
WO WO2020172596A1
· 2020
[cited by applicant]
WO WO2020227457A1
· 2020
[cited by applicant]
WO WO2021032960A1
· 2021
[cited by applicant]
WO WO2021032961A1
· 2021
[cited by applicant]
WO WO2021032963A1
· 2021
[cited by applicant]
WO WO2021052995A1
· 2021
[cited by applicant]
WO WO2021173896A1
· 2021
[cited by applicant]
WO WO2021183845A1
· 2021
[cited by applicant]
WO WO2021231434A1
· 2021
[cited by applicant]
WO WO2022093888A1
· 2022
[cited by applicant]
WO WO2022122973A1
· 2022
[cited by applicant]
WO WO2022192225A1
· 2022
[cited by applicant]
Brinkmann, U. et al. The Making of Bispecific Antibodies. MAbs 9.2 (2017): 182-212 (Year: 2017).
[cited by examiner]
Engelberts, Patrick J et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine 52 (2020): 102625 (Year: 2…
[cited by examiner]
Paul, S. et al. Regulatory and Effector Functions of Gamma Delta T Cells and Their Therapeutic Potential in Adoptive Cellular Therapy for Cancer. International journal of cancer 139.5 (2016): 976-985 (Year: 2016).
[cited by examiner]
Allison et al., “Structure of a human γδ T-cell antigen receptor”, Nature. Jun. 14, 2001, vol. 411, 820-824.
[cited by applicant]
Beckman Coulter, Inc., “TCR Vgamma 9”, https://www.beckmancoulter.com/wsrportal/page/itemDetails?itemNumber=IM1463#2/10//0/25/1 /0/asc/2/IM14631//0/1//0/, retrieved on Sep. 26, 2014, 1 page.
[cited by applicant]
Bedouelle et al., “Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus”, FEBS J. (2006); 273(1):34-46.
[cited by applicant]
Brown, M. et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2: A Means of Minimizing B Cell Wastage from Somatic Hypermutation”, The Journal of Immunology (1996); 156(9):3285-3291.
[cited by applicant]
Chatalic et al. “A Novel
[cited by applicant]
Colman, P.M. (1994) “Effects of amino acid sequence changes on antibody-antigen interactions” Research in Immunology, 145(1):33-36.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Application No. 15 722 781.0, dated Feb. 7, 2018, 5 pages.
[cited by applicant]
De Bruin, et al., “A Bispecific Nanobody Approach to Leverage the Potent and Widely Applicable Tumor Cytolytic Capacity of Vγ9Vδ2-T Cells” Oncoimmunology, Sep. 11, 2017, pp. 1-38.
[cited by applicant]
De Bruin et al., “Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications” Clinical Immunology, Aug. 2016, pp. 128-138.
[cited by applicant]
De Bruin et al., “Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody”, J Immunol., Jan. 1, 2017;198(1):308-317.
[cited by applicant]
Dondelinger et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Frontiers in Immunology, Oct. 2018, 9: 2278, 15 pages.
[cited by applicant]
Edwards, B.M. et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” Journal of Molecular Biology, Nov. 14, 2003, 334(1), pp…
[cited by applicant]
Ferrini et al., “Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies”, Int. J. Cancer: 44, 245-250 (1989).
[cited by applicant]
Ferrini et al., “Monoclonal antibodies which react with the T cell receptor y/o recognize different subsets of CD3+WT31-T lymphocytes”, Eur. J. Immunol. 1989. 19:57-61.
[cited by applicant]
Haberkorn et al., “New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy”, Clin Cancer Res., Jan. 1, 2016;22(1):9-15.
[cited by applicant]
Harlow et al., “Antibody Response”, Chapter 4, and “Immunizations”, Chapter 5, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, pp. 37-47, 55-59.
[cited by applicant]
Hernandez-Hoyos, G., et al., “MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer,” Molecular Cancer Therapeutics, Sep. 2016, vol. 15(9), pp. 215…
[cited by applicant]
International Search Report and Written Opinion, PCT/EP2021/068960, Nov. 3, 2021, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/EP2021/085079, Mar. 11, 2022, 13 pages.
[cited by applicant]
International Search Report issued to International Application No. PCT/NL2015/050235, mailed Jul. 10, 2015, 6 pages.
[cited by applicant]
Kabelitz et al., “Cancer immunotherapy with [gamma][delta] T cells: many paths ahead of us”, Cell Mol Immunol., Sep. 2020;17(9):925-939. Epub Jul. 22, 2020.
[cited by applicant]
Langerak, et al., “Immunophenotypic and immunogenotypic characteristics of TCRyo+ T cell acute lymphoblastic leukemia”, Leukemia (1999); 13, 206-214.
[cited by applicant]
Lloyd, C., et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens”, Protein Engineering, Design and Selection, Mar. 2009,…
[cited by applicant]
Miossec et al., “Further analysis of the T cell receptor gamma/delta+ peripheral lymphocyte subset. The V delta 1 gene segment is expressed with either C alpha or C delta”, J. Exp. Med., vol. 171, Apr. 1990, 1171-1188.
[cited by applicant]
Muyldermans, S. (2013) “Nanobodies: Natural Single-Domain Antibodies”. Annu Rev Biochem, 82:775-797.
[cited by applicant]
Muyldermans, S., “Single domain camel antibodies: current status,” Rev. Mol. Biotechnol. 74:277-302, 2001.
[cited by applicant]
Oberg et al., “Novel Bispecific Antibodies Increase yo T-Cell Cytotoxicity against Pancreatic Cancer Cells”, Cancer Res; 74(5); 1349-60, 2014.
[cited by applicant]
PE Anti-human TCR Vδ2 Antibody (BioLegend). 2012, 3 pages, URL at https://www.biolegend.com/fr-ch/products/pe-anti-human-tcr-vdelta2-antibody-4571?GroupID=BLG13659.
[cited by applicant]
Roovers et al., “Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies,” Cancer Immunol Immunother, Mar. 2007; 56(3): 303-17.
[cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences (1982); 79(6): 1979-1983.
[cited by applicant]
Saerens et al., “Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies”, J. Mol. Biol. (2005) 352, 597-607.
[cited by applicant]
Silva-Santos, et al., “[gamma][delta] T cells: pleiotropic immune effectors with therapeutic potential in cancer”, Nat Rev Cancer. Jul. 2019;19(7):392-404.
[cited by applicant]
Smolarek et al., Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine?* , Postepy Hig Med Dosw (online), 2012; 66: 348-358.
[cited by applicant]
Szereday, L. et al., “γ/δ T cell subsets in patients with active
[cited by applicant]
Tamura, M. et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,” J…
[cited by applicant]
Vajdos, F. F., et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis”, Journal of Molecular Biology (2002); 320(2): 415-428.
[cited by applicant]
Vecchi, Maurizio, et al., Increased Jejunal Intraepithelial Lymphocytes Bearing y/o T-Cell Receptor in Dermatitis Herpetiformis, Gastroenterology, 1992; 102:1499-1505.
[cited by applicant]
Viale et al., “TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation”, Bone Marrow Transplantation 1992, 10:249-253.
[cited by applicant]
Vincke, C. et al., “General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold”, J Biol Chem. (2009); 284(5):3273-3284.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/NL2015/050235, mailed Jul. 10, 2015, 8 pages.
[cited by applicant]
Wrobel, P., et al., “Lysis of a Broad Range of Epithelial Tumour Cells by Human gamma delta T Cells: Involvement of NKG2D ligands and T-cell Receptor-versus NKG2D-dependent Recognition”, Scandinavian Journal of Immunolo…
[cited by applicant]
Zabetakis et al., “Contributions of the Complementarity Determining Regions to the Thermal Stability of a Single-Domain Antibody”, PLOS ONE, Oct. 2013, vol. 8, Issue 10, e77678, 1-7.
[cited by applicant]
Zhou et al., “Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies”, Cellular & Molecular Immunology (2012) 9, 34-44.
[cited by applicant]